

# Contents

Preface      xvii  
In Memoriam      xix  
About the Authors      xxi

**CHAPTER 1 The Power of Bacteria** 2

Why Are Bacteria So Much in the Public Health Spotlight Nowadays?      3

Bacteria, a Formidable Ancient Life Form      4

Pressing Current Infectious Disease Issues      6

Emerging and Reemerging Infectious Diseases      6

Foodborne and Waterborne Infections      7

Modern Medicine as a Source of New Diseases      8

Postsurgical and Other Wound Infections      9

Bioterrorism      10

A New Respect for Prevention      10

Surveillance: An Early Warning System      11

Making Hospitals Safe for Patients      12

And Now for Some Good News: You've Got a Bacterial Infection!      12

The *Helicobacter pylori* Revolution      12

The Aftermath      13

Microbiota Shift Diseases      13

A Brave New World of Pathogenesis Research      14

The New Age of Genomics      16

Insights into Pathogen Evolution      17

Modeling the Host-Pathogen Interaction in Experimental Animals      17

Correlation Studies      18

Selected Readings      18

Questions      20

**CHAPTER 2 Skin and Mucosa: The First Lines of Defense against Bacterial Infections** 22

The Best Defense: Avoid, Reduce, and Prevent Exposure!      23

Barriers: Skin and Mucosal Membranes      24

The Layers of Cells That Protect the Body      24

Normal Microbiota of the Skin and Mucosa      27

Defenses of the Skin      31



|  |    |
|--|----|
| Defenses of Mucosal Surfaces                     | 32 |
| Special Defenses of the Gastrointestinal Tract   | 34 |
| Special Defenses of the Urogenital Tract         | 36 |
| Special Defenses of the Respiratory Tract        | 36 |
| Immune Defenses of the Skin and Mucosa           | 37 |
| Models for Studying Breaches of Barrier Defenses | 38 |
| Selected Readings                                | 39 |
| Questions  | 39 |

### CHAPTER 3 The Innate Immune System: Always on Guard

40

|  |    |
|--|----|
| Triggering Innate Immune Defenses                                      | 41 |
| Innate Immune Cells That Defend Blood and Tissue                       | 42 |
| Neutrophils (PMNs)   | 42 |
| Monocytes, Macrophages, and Dendritic Cells (DCs)                      | 42 |
| Granulocytes: Basophils, Mast Cells, and Eosinophils                   | 47 |
| Transmigration—How Do Phagocytes Know When and Where to Go?            | 47 |
| Natural Killer (NK) Cells  | 48 |
| The Lymphatic System   | 50 |
| How Phagocytes Recognize and Respond to Bacteria                       | 50 |
| How Phagocytes Kill Bacteria   | 54 |
| Oxidative Burst in Phagolysosomes                                      | 54 |
| Autophagy—Another Pathway for the Killing of Intracellular Pathogens   | 56 |
| The Complement Cascade   | 57 |
| Complement Proteins  | 57 |
| Overview of Complement Pathways and Their Function                     | 58 |
| Steps in Complement Activation   | 60 |
| Controlling Complement Activation                                      | 62 |
| Cytokines and Chemokines—Mediators of Immune Responses                 | 63 |
| Roles of Cytokines and Chemokines in Directing Innate Immune Responses | 63 |
| Inflammation and Collateral Damage                                     | 65 |
| Septic Shock: The Dark Side of the Innate Defenses                     | 66 |
| Other Innate Defenses of the Body—Nutritional Immunity                 | 69 |
| Selected Readings  | 70 |
| Questions  | 70 |

### CHAPTER 4 The Adaptive Defenses: Antibodies and Cytotoxic T Cells

72

|   |    |
|---|----|
| The Specialists: Adapting to a Particular Pathogen Challenge                  | 73 |
| B Cells: Producers of Antibodies  | 74 |
| The Humoral (Antibody) Immune Response  | 74 |
| Characteristics of Antibodies and Their Diverse Roles in Preventing Infection | 74 |
| Serum Antibodies  | 76 |
| Secretory Antibodies: Antibodies That Protect Mucosal Surfaces                | 78 |
| Pathogen and Toxin Neutralization by Antibodies                               | 79 |
| Affinity and Avidity  | 80 |
| Cytotoxic T Cells, Also Known as Cytotoxic T Lymphocytes (CTLs)               | 81 |
| Cytotoxic T Lymphocytes: Critical Defense against Intracellular Pathogens     | 81 |
| Antigen Presentation to the Immune System                                     | 82 |
| Processing of Protein Antigens by Dendritic Cells                             | 82 |
| Interaction between APCs and T Cells: The T-Cell-Dependent Response           | 84 |
| Th-(Th1/Th2/Th17)-Cell-Mediated Immunity                                      | 86 |
| Production of Antibodies by B Cells   | 87 |
| Links between the Innate and Adaptive Defense Systems                         | 88 |



|   |    |
|---|----|
| T-Cell-Independent Antibody Responses                               | 89 |
| Mucosal Immunity: IgA/sIgA Antibodies                               | 89 |
| Development of the Adaptive Immune System from Infancy to Adulthood | 92 |
| Adaptive Defense Systems in Nonmammals                              | 93 |
| The Dark Side of the Adaptive Defenses: Autoimmune Disease          | 93 |
| Selected Readings   | 94 |
| Questions   | 94 |
| Solving Problems in Bacterial Pathogenesis                          | 95 |

## **CHAPTER 5 The Microbiota of the Human Body: Microbiomes and Beyond** 98

|  |     |
|--|-----|
| Importance of the Normal Resident Microbial Populations (Microbiota) of the Human Body | 99  |
| Characterization of the Body's Microbiota  | 100 |
| Taking a Microbial Census by Using Microbial rRNA Gene Sequence Analysis               | 101 |
| Characterizing Microbiomes by Using Metagenomic Analysis                               | 115 |
| Beyond the Metagenome  | 117 |
| Overview of the Human Microbiota   | 123 |
| Skin Microbiota  | 124 |
| Oropharyngeal Microbiota   | 125 |
| Microbiota of the Small Intestine and Colon  | 125 |
| Microbiota of the Vaginal Tract  | 128 |
| The Other Microbiota: The Forgotten Eukaryotes   | 130 |
| Selected Readings  | 130 |
| Questions  | 131 |
| Solving Problems in Bacterial Pathogenesis   | 133 |

## **CHAPTER 6 Microbes and Disease: Establishing a Connection** 134

|   |     |
|---|-----|
| History and Relevance of Koch's Postulates  | 136 |
| Early Germ Theory   | 136 |
| Koch's Postulates: A Set of Criteria Used To Establish a Microbe-Disease Connection                         | 137 |
| Challenges to Satisfying Koch's Postulates  | 138 |
| Easier Said than Done . . .   | 138 |
| The First Postulate: Association of the Microbe with Lesions of the Disease                                 | 139 |
| The Second Postulate: Isolating the Bacterium in Pure Culture   | 140 |
| The Third Postulate: Showing that the Isolated Bacterium Causes Disease Experimentally in Humans or Animals | 141 |
| The Fourth Postulate: Reisolating the Bacterium from the Intentionally Infected Animal                      | 143 |
| Modern Alternatives To Satisfy Koch's Postulates  | 143 |
| Detecting the Presence of the Pathogen Only in Diseased Tissues   | 143 |
| Eliminate the Pathogen and Prevent or Cure the Disease  | 144 |
| Comparative Infectious Disease Causation  | 147 |
| The Microbiota Shift Disease Problem  | 147 |
| Koch's Postulates and Pathogenic Microbial Communities  | 147 |
| Keystone Pathogens and Microbial Shift Diseases   | 147 |
| Molecular Koch's Postulates   | 149 |
| Concepts of Disease   | 150 |
| Varieties of Human-Microbe Interactions   | 150 |
| Views of the Human-Microbe Interaction  | 150 |
| Virulence as a Complex Phenomenon   | 152 |
| Selected Readings   | 152 |
| Questions   | 153 |
| Solving Problems in Bacterial Pathogenesis  | 153 |



|  |            |
|--|------------|
| <b>CHAPTER 7 Mechanisms of Genetic Modification and Exchange: Role in Pathogen Evolution</b>     | <b>156</b> |
| Adapt or Perish  | 158        |
| Acquiring New Virulence Traits by Horizontal Gene Transfer                                       | 158        |
| Mechanisms of Genetic Change and Diversification   | 158        |
| Spontaneous Mutation   | 158        |
| Phase Variation  | 159        |
| Antigenic Variation  | 161        |
| Horizontal Gene Transfer: Mobile Genetic Elements  | 162        |
| Natural Transformation   | 162        |
| Conjugation: Plasmids and Transposons  | 165        |
| Phage Transduction   | 171        |
| Control of Horizontal Gene Transfer  | 171        |
| Toxin-Antitoxin Systems—Retaining the Goods  | 171        |
| Restriction-Modification Systems—Bacterial Innate Immunity from Foreign DNA                      | 173        |
| CRISPR-Cas Systems—Bacterial Adaptive Immunity from Foreign DNA                                  | 173        |
| Type 6 Secretion Systems—Bacterial Defense Against Conjugation                                   | 174        |
| Pathogenicity Islands and Pathogen Evolution   | 174        |
| Properties of Pathogenicity Islands  | 174        |
| Pathogen Evolution in Quantum Leaps  | 177        |
| Selected Readings  | 178        |
| Questions  | 179        |
| Solving Problems in Bacterial Pathogenesis   | 179        |
| <b>CHAPTER 8 Identification of Virulence Factors: Measuring Infectivity and Virulence</b>        | <b>182</b> |
| How Does One Experimentally Measure Virulence and Satisfy Koch's Postulates?                     | 183        |
| Animal Models of Infection   | 184        |
| Human Volunteers   | 184        |
| Nonhuman Animal Models   | 186        |
| Measuring Bacterial Infection in Animal Models   | 188        |
| Ethical Considerations   | 188        |
| Animal Model Basics  | 188        |
| Survival Curve Analysis and Biophotonic Imaging  | 189        |
| ID <sub>50</sub> and LD <sub>50</sub> Values   | 190        |
| Competition Assays   | 191        |
| Tissue Culture and Organ Culture Models  | 192        |
| Tissue Culture Models  | 192        |
| Gentamicin Protection Assay for Cell Adhesion and Invasion                                       | 193        |
| Plaque Assay for Intracellular Survival and Cell-to-Cell Spread                                  | 195        |
| Fluorescence Microscopy Techniques for Assessing Effects of Pathogens on Host Cells              | 196        |
| Organ Culture Models   | 196        |
| The Continuing Need for Reliable and Plentiful Information about Disease Pathology               | 197        |
| Selected Readings  | 198        |
| Questions  | 199        |
| Solving Problems in Bacterial Pathogenesis   | 200        |
| <b>CHAPTER 9 Identification of Virulence Factors: Molecular Approaches for Bacterial Factors</b> | <b>202</b> |
| Finding a Needle in a Haystack   | 204        |
| Biochemical Approaches   | 204        |
| Isolation and Purification of Toxic Factors  | 204        |
| Molecular Genetic Approaches   | 208        |
| Screening Using Recombinant Genes  | 208        |
| Reporter Fusions   | 208        |



|  |            |
|--|------------|
| Mutagenesis Screening  | 210        |
| <b>Genome-wide Sequencing Approaches for Identifying Virulence Genes</b>                     | <b>214</b> |
| Tn-Seq Technology to Identify <i>In Vivo</i> -Expressed Genes                                | 214        |
| RNA-Seq Technology to Identify <i>In Vivo</i> -Expressed Genes                               | 216        |
| Comparative Genomic Sequence Analysis for Identifying Virulence Genes                        | 217        |
| <b>Proteomics Approaches for Identifying Virulence Factors</b>                               | <b>218</b> |
| Protein Microarrays (Proteomicroarrays)  | 218        |
| <i>In Vivo</i> -Induced Antigen Technology (IVIAT)   | 218        |
| <b>The Importance of Understanding Bacterial Physiology</b>                                  | <b>219</b> |
| <b>Selected Readings</b>   | <b>222</b> |
| <b>Questions</b>   | <b>223</b> |
| <b>Solving Problems in Bacterial Pathogenesis</b>  | <b>223</b> |
| <b>CHAPTER 10 Identification of Virulence Factors: Molecular Approaches for Host Factors</b> | <b>226</b> |
| <b>Comparative Approaches to Identify Host Factors Required for Infection</b>                | <b>227</b> |
| Transgenic Animal Models   | 228        |
| <i>In vivo</i> Imaging of Animals during Infection   | 231        |
| Systems Genetics: Comparative Genomics of the Host Response                                  | 231        |
| <b>Screening Approaches to Identify Host Factors Required for Infection</b>                  | <b>235</b> |
| Genome-Wide Screening  | 235        |
| <b>Host Response Profiling to Identify Host Factors Required for Infection</b>               | <b>240</b> |
| Transcriptomics  | 240        |
| Proteomics   | 243        |
| Metabolomics   | 246        |
| <b>The Promise and the Caution</b>   | <b>247</b> |
| <b>Selected Readings</b>   | <b>248</b> |
| <b>Questions</b>   | <b>249</b> |
| <b>Solving Problems in Bacterial Pathogenesis</b>  | <b>249</b> |
| <b>CHAPTER 11 Bacterial Strategies for Colonization and Survival in the Host</b>             | <b>254</b> |
| <b>What Does Not Kill You Makes You Stronger—Or, a Better Pathogen</b>                       | <b>255</b> |
| <b>Preinfection</b>  | <b>258</b> |
| Survival in the External Environment   | 258        |
| Biofilms   | 258        |
| Motility and Chemotaxis  | 260        |
| <b>Colonization of Host Surfaces</b>   | <b>263</b> |
| Penetrating Intact Skin  | 263        |
| Penetrating the Mucin Layer  | 263        |
| Evading the Host's Innate Immunity   | 264        |
| Nutrient and Iron Acquisition Mechanisms   | 265        |
| Adherence  | 268        |
| <b>Evading the Host Immune Response</b>  | <b>275</b> |
| Avoiding Complement and Phagocytosis   | 277        |
| Invasion and Uptake by Host Cells  | 280        |
| Surviving Phagocytosis   | 281        |
| Cell-to-Cell Spread  | 286        |
| Tissue Penetration and Dissemination   | 288        |
| Beyond Virulence Factors   | 288        |
| <b>Selected Readings</b>   | <b>289</b> |
| <b>Questions</b>   | <b>290</b> |
| <b>Solving Problems in Bacterial Pathogenesis</b>  | <b>290</b> |
| <b>Special Global Perspective Problem: Integrating Concepts in Pathogenesis</b>              | <b>291</b> |



**CHAPTER 12 Toxins and Other Toxic Virulence Factors 294**

|  |            |
|--|------------|
| <b>Bacterial Toxins</b>  | <b>295</b> |
| Transparent Mechanisms, Exciting Applications, Mysterious Purposes | 295        |
| Toxin Characteristics and Nomenclature                             | 300        |
| Nonprotein Toxins  | 302        |
| Peptide and Protein Exotoxins                                      | 304        |
| Toxic Effector Proteins of Specialized Secretion Systems           | 312        |
| <b>Examples of Toxin-Mediated Diseases</b>                         | <b>313</b> |
| Diphtheria Toxin   | 313        |
| Clostridial Neurotoxins  | 319        |
| Cholera Toxin  | 323        |
| <b>Toxin-Based Therapeutics and Research Tools</b>                 | <b>327</b> |
| Immunotoxins   | 327        |
| <b>Selected Readings</b>   | <b>329</b> |
| <b>Questions</b>   | <b>330</b> |
| <b>Solving Problems in Bacterial Pathogenesis</b>                  | <b>331</b> |

**CHAPTER 13 Delivery of Virulence Factors 334**

|  |            |
|--|------------|
| <b>Bacterial Secretion Systems and Virulence</b>                             | <b>335</b> |
| <b>Common Secretory Systems</b>  | <b>336</b> |
| The General Secretory (Sec) System   | 336        |
| The Accessory Secretory (Sec) System   | 336        |
| The Cotranslational Signal-Recognition Particle (SRP) System                 | 336        |
| The Twin-Arginine Transport (TAT) System                                     | 337        |
| <b>Secretion Systems Specific to Gram-Negative Bacteria</b>                  | <b>338</b> |
| Sec-Dependent Secretion Systems  | 338        |
| Sec-Independent Secretion Systems  | 341        |
| <b>Specialized Secretion Systems Specific to Gram-Positive Bacteria</b>      | <b>350</b> |
| General Secretory Transporter Systems in Gram-Positive Bacteria              | 350        |
| Cytolysin-Mediated Translocation (CMT) in <i>S. pyogenes</i> (Group A Strep) | 351        |
| Type 7 Secretion System (T7SS)   | 352        |
| <b>Selected Readings</b>   | <b>353</b> |
| <b>Questions</b>   | <b>354</b> |
| <b>Solving Problems in Bacterial Pathogenesis</b>                            | <b>355</b> |

**CHAPTER 14 Virulence Regulation 360**

|  |            |
|--|------------|
| <b>Virulence Gene Regulation</b>                                 | <b>361</b> |
| <b>Mechanisms of Regulation</b>                                  | <b>361</b> |
| Operons, Regulons, and Global Regulators                         | 362        |
| Activators and Repressors  | 362        |
| Two-Component Regulatory Systems                                 | 364        |
| Sigma Factors  | 368        |
| Transcriptional Terminators and Antiterminators                  | 369        |
| Regulation of Translation Initiation                             | 372        |
| Regulatory Small RNAs  | 372        |
| Bacterial Chromatin  | 375        |
| <b>Responding to Environmental Signals</b>                       | <b>376</b> |
| Phase Variation and Bistable Switches                            | 376        |
| Hypermutable, Intragenomic Recombination, and Positive Selection | 377        |
| Coordinate Virulence Regulation                                  | 377        |
| Quorum Sensing   | 378        |
| Chemotaxis   | 387        |
| <b>Selected Readings</b>   | <b>389</b> |
| <b>Questions</b>   | <b>389</b> |



|   |     |
|---|-----|
| Solving Problems in Bacterial Pathogenesis                                | 390 |
| Special Global Perspective Problems: Integrating Concepts in Pathogenesis | 395 |

## CHAPTER 15 Antimicrobial Compounds and Their Targets 400

|  |     |
|--|-----|
| Antimicrobial Compounds: The Safety Net of Modern Medicine | 401 |
| The Importance of Antimicrobial Compounds                  | 401 |
| Avoiding, Reducing, and Preventing Exposure                | 402 |
| Killing versus Inhibiting Growth                           | 404 |
| Tests Used To Assess Antibiotics                           | 404 |
| Antiseptics and Disinfectants                              | 405 |
| Antibiotics  | 407 |
| Characteristics of Antibiotics                             | 407 |
| The Process of Antibiotic Discovery                        | 409 |
| The Economics of Antibiotic Discovery                      | 413 |
| Mechanisms of Antibiotic Action                            | 416 |
| Targets of Antibiotic Action                               | 416 |
| Cell Wall Synthesis Inhibitors                             | 417 |
| Protein Synthesis Inhibitors                               | 422 |
| Antibiotics That Target DNA and RNA Synthesis              | 425 |
| Inhibitors of Tetrahydrofolate Biosynthesis                | 429 |
| The Newest Antibiotics                                     | 429 |
| The Newest Antibiotic Targets                              | 430 |
| Strategies for Enhancing Antibiotic Efficacy               | 431 |
| The Continuing Challenge                                   | 432 |
| Selected Readings  | 433 |
| Questions  | 434 |
| Solving Problems in Bacterial Pathogenesis                 | 435 |

## CHAPTER 16 Antibiotic Resistance 436

|   |     |
|---|-----|
| The Dawning of Awareness—Uh, We Have a Problem!   | 437 |
| How Did We Get to Where We Are?   | 438 |
| And Now the Really Scary Part . . .   | 440 |
| Emergence and Challenge of Multidrug Resistance (MDR)   | 440 |
| Multiple Resistance and Genetic Linkage   | 441 |
| Next-Generation MDR Pathogens: The “Superbugs”!   | 441 |
| Mechanisms of Antibiotic Resistance   | 444 |
| Overview of Resistance Mechanisms   | 444 |
| Resistance to Antiseptics and Disinfectants   | 444 |
| Limiting Access of the Antibiotic   | 445 |
| Enzymatic Inactivation of the Antibiotic  | 446 |
| Modification or Protection of the Antibiotic Target   | 451 |
| Failure to Activate an Antibiotic   | 453 |
| Regulation of Resistance Genes  | 454 |
| Antibiotic Tolerance and Persister Cells  | 457 |
| Antibiotic Tolerance  | 457 |
| Persistence   | 459 |
| Toxin-Antitoxin Systems   | 459 |
| Horizontal Gene Transfer (HGT) of Resistance Genes  | 461 |
| Propagating and Maintaining Antibiotic Resistance through Selective Pressure and Changes in Fitness | 463 |
| Will We Return to the Pre-Antibiotic Era?   | 464 |
| Returning to Status Quo or Moving Forward?  | 464 |
| The Hunt for Alternative Approaches to Antibiotics  | 466 |



|   |     |
|---|-----|
| Selected Readings   | 468 |
| Questions   | 469 |
| Solving Problems in Bacterial Pathogenesis                                | 470 |
| Special Global Perspective Problems: Integrating Concepts in Pathogenesis | 470 |

## CHAPTER 17 Vaccination: A Critical Component of the Modern Medical Armamentarium 476

|   |     |
|---|-----|
| Vaccines: A Major Health Care Bargain                                     | 477 |
| What Makes an Ideal Vaccine?  | 479 |
| Immunization Programs   | 480 |
| Barriers to Implementation and Success of Immunization Programs           | 483 |
| The Antivaccination Movement  | 484 |
| Vaccine Success Stories   | 485 |
| Subunit Vaccines  | 485 |
| Conjugate Vaccines  | 490 |
| Vaccine “Less-than-Success” Stories                                       | 492 |
| A New Age of Vaccine Development: Making Vaccines Better                  | 494 |
| Approaches to Enhancing Immunogenicity                                    | 494 |
| Adjuvants   | 494 |
| Programming Adaptive Immunity   | 496 |
| Targeting Mucosal Immunity  | 500 |
| Storage of Vaccines—Strategies to Increase Shelf Life                     | 504 |
| Passive Immunization  | 504 |
| Selected Readings   | 505 |
| Questions   | 505 |
| Solving Problems in Bacterial Pathogenesis                                | 508 |
| Special Global Perspective Problems: Integrating Concepts in Pathogenesis | 510 |

## CHAPTER 18 The Gram-Positive Opportunistic Pathogens 514

|  |     |
|--|-----|
| What Is an Opportunist?  | 515 |
| Characteristics of Gram-Positive Opportunists                      | 516 |
| Notable Gram-Positive Opportunists                                 | 516 |
| <i>Staphylococcus aureus</i> —Commensal Ready for a Fight          | 516 |
| <i>Staphylococcus epidermidis</i> —Accidental Pathogen             | 524 |
| <i>Streptococcus pneumoniae</i> —“Captain of All the Men of Death” | 527 |
| <i>Clostridium difficile</i> —True Opportunist                     | 534 |
| Other Gram-Positive Opportunists                                   | 542 |
| Selected Readings  | 543 |
| Questions  | 544 |
| Solving Problems in Bacterial Pathogenesis                         | 544 |

## CHAPTER 19 The Gram-Negative Opportunistic Pathogens 548

|  |     |
|--|-----|
| Jumping Over the (Cell) Wall: Gram-Negative Bacteria Can Be Opportunistic Pathogens Too! | 549 |
| Common Traits of Gram-Negative Opportunists  | 549 |
| The Dark Side of Some Residents of the Human Body  | 550 |
| The Ever-Changing Face of <i>E. coli</i>   | 550 |
| <i>Klebsiella pneumoniae</i> Nosocomial Infections                                       | 554 |
| <i>Bacteroides fragilis</i> —The Bad Sheep of the Family                                 | 555 |
| <i>Porphyromonas gingivalis</i> —A Keystone Pathogen                                     | 557 |
| Environmental Inhabitants Weigh in as Opportunists                                       | 558 |
| <i>Pseudomonas aeruginosa</i> —A Versatile Opportunist of the Highest Order              | 558 |
| <i>Burkholderia cepacia</i> Complex— <i>P. aeruginosa</i> ’s Evil Twin                   | 565 |



|   |     |
|---|-----|
| <i>Acinetobacter baumannii</i> —A Deadly Threat Emerges from the Iraq War | 565 |
| Don't Forget the Arthropods!  | 567 |
| <i>Ehrlichia</i> spp.   | 567 |
| Selected Readings   | 568 |
| Questions   | 569 |
| Solving Problems in Bacterial Pathogenesis                                | 569 |
| Special Global Perspective Problems: Integrating Concepts in Pathogenesis | 570 |

## **CHAPTER 20 The Changing Roles of Microbiologists in an Age of Bioterrorism and Emerging Diseases**

574

|   |     |
|---|-----|
| When Microbiologists Are Called to the Front Line           | 575 |
| Tracking Down a Bioterrorist                                | 576 |
| Unintentional or Deliberate?                                | 577 |
| Timing  | 579 |
| Tracing the Source  | 579 |
| Lessons Learned   | 579 |
| The "Top Four" Bioterror Agents                             | 582 |
| <i>Bacillus anthracis</i> Spores                            | 582 |
| Smallpox  | 583 |
| <i>Yersinia pestis</i>                                      | 583 |
| Botulinum Neurotoxin  | 584 |
| What If Bioterrorists Hit Us with Something Completely New? | 585 |
| Biosecurity in a Complex, Dynamic, and Ever-Changing World  | 585 |
| Food Safety and Biosecurity                                 | 586 |
| The Case for Food Irradiation                               | 587 |
| The Future of Biosecurity                                   | 589 |
| Selected Readings   | 589 |
| Questions   | 590 |
| Solving Problems in Bacterial Pathogenesis                  | 591 |

Glossary 593

Index 661